Study of Linagliptin Combined with Insulin Therapy in Patients with Type 2 Diabetes and Renal Impairment
ZHU Guang-ping
XIANG Guang-da
YUE Ling
ZHANG Jun-xia
Abstract：Objective To evaluate the efficacy and safety of Linagliptin in patients with type 2 diabetes mellitus (T2DM) and diabetic nephropathy.Methods Sixty T2DM patients with proteinuria were randomly divided into treatment group (insulin plus Linagliptin) and control group (insulin plus placebo) for 12 weeks.Body mass, blood glucose, kidney function, microalbuminuria (M-Alb), C-peptide levels, insulin dose were measured before and after the treatment.Adverse events were also recorded to assess the safety of the treatment programs.Results Both two treatment programs effectively reduced fasting blood glucose(FBG), 2-hour plasma glucose(2hPG), glycosylated hemoglobin A1c (HbA1c) (P<0.01).There were no significant difference in M-Alb and creatinine clearance rate (Ccr) before and after treatment in two groups (P>0.05).Compared the control group, body mass increasing range and insulin dose were less in Linagliptin group (P<0.05).Conclusion Two treatment methods can effectively control blood glucose levels without increasing risks of renal impairment.However, Linagliptin plus insulin therapy has advantage in reducing insulin dose, controlling body mass, reducing risk of hypoglycemia.
Keywords：LinagliptinInsulinRenal impairmentType 2 diabetes mellitusMicroalbuminuria
Publication Date：2017-01-01
Pages：5( 240-243,256 )